Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects With PKU

Trial Profile

Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects With PKU

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Pegvaliase (Primary)
  • Indications Phenylketonuria
  • Focus Therapeutic Use
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 11 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 30 Mar 2015 According to a BioMarin media release, data from this study were presented at the 2015 American College of Medical Genetics and Genomics Annual Conference.
    • 01 Feb 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top